NASDAQ:ADMS
Delisted
Adamas Pharmaceuticals Stock News
$8.22
+0 (+0%)
At Close: May 27, 2022
New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's Disease
09:15am, Thursday, 10'th Jun 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
Adamas to Present at Upcoming June Conferences
04:11pm, Thursday, 27'th May 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
ADMS Stock: Over 9% Increase Intraday Explanation
02:56pm, Tuesday, 11'th May 2021
The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 9% during intraday trading. This is why it happened.
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q1 2021 Results - Earnings Call Transcript
09:52pm, Monday, 10'th May 2021
Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q1 2021 Results - Earnings Call Transcript
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates
06:02pm, Monday, 10'th May 2021
Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Adamas Announces New Employment Inducement Grant
04:05pm, Friday, 07'th May 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted five new employees restrict
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy?
03:47pm, Monday, 03'rd May 2021
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting
09:15am, Thursday, 15'th Apr 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
Adamas to Present at Upcoming Needham Conference
05:19pm, Wednesday, 07'th Apr 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
Adamas Announces New Employment Inducement Grant
04:02pm, Friday, 05'th Mar 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees restricte
Strength Seen in Adamas (ADMS): Can Its 5.9% Jump Turn into More Strength?
06:49am, Tuesday, 02'nd Mar 2021
Adamas (ADMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering
09:16pm, Wednesday, 24'th Feb 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering
04:08pm, Wednesday, 24'th Feb 2021
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neu
